Purpose-Patients with cancer who graciously consent for autopsy represent an invaluable resource for the study of cancer biology. To advance the study of tumor evolution, metastases, and resistance to treatment, we developed a next-generation rapid autopsy program integrated within a broader precision medicine clinical trial that interrogates pre-and postmortem tissue samples for patients of all ages and cancer types.
INTRODUCTION
The ability to comprehensively interrogate an individual patient's cancer at molecular resolution is enabled by rapidly advancing sequencing technologies. The goal of the Caryl and Israel Englander Institute for Precision Medicine (IPM; New York, NY) is to harness as much information as possible from an individual patient's tumor tissue not only in an effort to benefit the patient during life, 1 but also to develop preclinical platforms 2 and coclinical trials with the potential to benefit larger populations. An important arm of our precision medicine program permits postmortem tissue donation linked to robust downstream applications through a dedicated autopsy program.
Institutional rapid autopsy programs have been well described 1, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and have previously led to significant advances in cancer research in the areas of prostate, 1, 3, 4, 6, 7, 11 pancreas, 10 breast, 8 and pediatric brain tumors. 5, 9, 12 This program builds on prior autopsy programs by enrolling patients of all ages and cancer types, capturing samples throughout a patient's disease course, and leveraging multiple parallel platforms to generate high-throughput sequencing data and robust preclinical tumor models. We highlight our initial experience with 15 patients who underwent rapid autopsy and emphasize the following three themes: capturing the molecular status of a diverse set of neoplasms at the end point in disease progression relative to samples acquired earlier in the course of disease; the comparison of primary tumors to a multiplicity of metastatic sites at the molecular level to study processes underlying metastatic spread and organ-specific tumor tropism; and the development of tumor organoid models 2 and patient-derived xenografts (PDXs), with the potential for highthroughput drug screening and functional validation studies.
MATERIALS AND METHODS

Basic Autopsy Protocol
Consent-At the time that patients consent to enroll in the Precision Medicine Program (Weill Cornell Medicine [WCM] Institution Review Board No. 1305013903), they may also consent for the Rapid Autopsy Program (Data Supplement). The discussion of consent for autopsy may also be held at a later time. At our institution, the generic hospital autopsy consent form must also be signed by the next of kin. This institutional review boardapproved autopsy tissue donor program is based in part on protocols developed at the University of Michigan by Drs Mark A. Rubin and Kenneth Pienta. 3, 4 Patient notification-Once the treating physician notifies a contact member of a patient's death by pager, a robotic calling system is activated to alert the autopsy team. Attending and resident autopsy pathologists, an autopsy technical assistant, and two to four members of the IPM laboratory are available at all times. The patients' treating oncologists and surgeons may also be present. The postmortem interval goal for in-house patients is less than 1 hour.
Tissue collection-Autopsy is performed using the en bloc Letulle dissection method. Tissues are snap frozen using Tissue-Tek O.C.T. embedding medium and Tissue-Tek cryomolds (Sakura Finetek, Torrance, CA). These are placed in a dry ice and methylbutane bath and stored at −80°C. 1, 6 In addition, fresh tissue is immediately transported to the laboratory for xenograft and tumor organoid development. 2 See Data Supplement for sample autopsy findings.
Nucleic Acid Extraction
DNA extraction and whole-exome and whole-genome sequencing-As previously described, 1 tumor and germline DNA is extracted using the Promega Maxwell 16 MDx DNA Purification Kits (Promega, Madison, WI). Sequencing is performed using Illumina HiSEquation 2500 Rapid Run Mode (2×101 bp; Illumina, San Diego, CA). Short reads are aligned to GRC37/hg19 reference using Burrows-Wheeler aligner and processed accordingly to IPM-Exome-pipeline v0.9 as previously published. 1, 13 Three DNA samples from patient WCM0 corresponding to two liver metastases (LMs; LM1 and LM2) and germline DNA from blood underwent whole-genome sequencing (WGS) at the New York Genome Center following the sequencing protocols and analyses described in this section. 14, 15 RNA extraction and RNA sequencing-Total RNA was prepared for RNA sequencing (RNA-Seq) in accordance with the standard Illumina mRNA sample preparation protocol (Illumina). Paired-end RNA-Seq at read lengths of 50 or 51 base pairs was performed with the HiSEquation 2000(Illumina). Approximately 268 million paired-end reads were generated, corresponding to approximately 27 billion bases. 16 
DNA Sequencing and Data Analysis
Sequence data processing pipeline-All exome data of the study samples were processed through the computational analysis pipeline of IPM, as previously described (IPM-Exome-pipeline v0.9). 1, 13 We implemented an approach to improve on single nucleotide variant calls in the presence of multisample patient data. 17, 18 WGS samples were analyzed at the New York Genome Center. 15, 19, 20 Phylogenetic analysis-Tumor samples are represented in a phylogenetic tree as nodes with no children, whereas the internal nodes model inferred tumor cell populations on the basis of observed single nucleotide variants using the parsimony ratchet method. 21, 22 See Data Supplement for gene clonality assessment.
RNA-Seq Data Analysis
All reads were independently aligned with STAR_2.4.0f1 23 for sequence alignment against the human genome build hg19, downloaded via the University of California Santa Cruz Genome Browser. For fusion analysis, we used STAR-fusion (STAR-Fusion_v0.5.1), 24, 25 FusionCatcher (v0.99.3e), 26 and FusionSeq. [27] [28] [29] [30] [31] Patient-Derived, Tumor Organoid, and Xenograft Development Platform As previously described, 2 
RESULTS
Consent
One hundred twenty-three (22%) of 554 patients who consented to the clinical trial have also consented for rapid autopsy. Of those patients for whom we have documented death in addition to premortem consent, we have performed autopsy on approximately 54% (see Materials and Methods for details on consent).
Diversity of Tumor Types and Metastatic Sites
The first 15 autopsies performed comprise a diverse set of neoplasms and metastatic sites (Fig 1) . Primary tumors were available in 12 (80%) of 15 patients from prior surgical resections and/or from recurrent or residual primary tumors obtained at autopsy. In patients with known metastatic disease before death, matched primary and metastatic tumor from individual patients was available in 10 (77%) of 13 patients, and metastatic disease was collected at autopsy in 100% (n = 13) of these patients. Patient ages ranged from less than 10 to greater than 89 years at death, and patients were variably treated with prior surgery, radiation, and/or chemotherapeutic agents (Data Supplement).
Tissue Collection and DNA/RNA Extraction Results
Overall postmortem time interval (PMI) ranged from 0.5 to 18 hours. PMI for in-house patients averaged 3.1 hours (range, 0.5 to 6.5 hours), and PMI for outside patients averaged 8.42 hours (range, 2 to 18 hours). Delays were primarily attributable to transportation, administrative wait times, and/or accommodations of requests by the patient's family. Transport was successfully managed from up to 50 miles from our Manhattan-based institution.
This initial cohort yielded a total of 346 frozen aliquots over 131 distinctly annotated anatomic sites, of which 310 contained tumor upon histologic review of frozen sections ( Fig  1B) . One hundred thirteen distinct samples underwent whole-exome sequencing (WES), including 82 frozen tumor and 10 frozen non-neoplastic control tissue samples obtained at autopsy, six samples derived from peripheral blood, and 15 formalin-fixed paraffinembedded or frozen samples from prior surgical procedures. DNA yield and quality are provided in the Data Supplement. In addition to WES, RNA-Seq was performed on a subset of samples (n = 72). Data regarding RNA concentration, RNA integrity number values, 260/280 values, and 260/230 values over all RNA samples are provided in the Data Supplement. Finally, three samples from patient WCM0 (two LMs and one blood normal) underwent WGS through the Illumina Genome Network.
Average Coverage and Capture Efficiency
Overall 99.5% (> 170 million) and 95.8% (> 70 million) of paired-end reads generated could be mapped. The average coverage and capture efficiency for each patient are provided in the Data Supplement. WGS was done at greater than 90× coverage for both tumor samples (LM1 approximately 105×, LM2 approximately 90×) and greater than 40× for the blood normal (approximately 45×), with mapping rates between 94.5% and 95.6%.
Collection of Rare Disease Entities
A unique aspect of tumor acquisition at autopsy is the ability to procure material in inoperable patients. A salient example is WCM627, a pediatric patient with an inoperable infiltrative astrocytoma centered within the pons. In this patient, 14 frozen tissue aliquots were procured from the primary tumor mass within the brainstem at autopsy. Despite transporting the patient from an outside institution, our PMI for this patient was only 2 hours, and the effort led to viable cell cultures.
Tumor Clonal Architecture and Evolution
Autopsy material in combination with premortem surgical material is crucial to the study of the spatiotemporal evolution of cancer. In our cohort, prior surgical material was available in 13 (87%) of 15 patients. In one illustrative patient (WCM419), a young girl with recurrent anaplastic ependymoma, material was available from eight distinct surgical resection procedures spanning more than 5 years in addition to material obtained at autopsy (Fig 2) . Multiple sites of disease were available for study including the posterior fossa (the primary site), metastatic lesions within the spinal cord, and a metastatic deposit involving the lateral ventricle obtained at autopsy (Figs 2A to 2C ). Histologic examination of all tumor material showed prominent perivascular pseudorosette formation (Fig 2D) . WES was performed on formalin-fixed paraffin-embedded material derived from prior surgical specimens as well as frozen autopsy tissue from two distinct sites (Figs 2E and 2F). Reconstruction of the evolutionary tree of this tumor revealed a complex branching pattern where several mutations (ERBB3, DNMT3A, BRCA1, NOTCH1, and RUNX1T1) in the primary tumor samples were not shared at different time points (0 to 64 months) or with descendent clones (Fig 2G) . Moreover, we identified two genes, CUL9 and PIGM, as harboring alterations specific to three or greater metastatic sites of disease and absent from all tissues resected from the primary site of disease.
Molecular Features Among Multiple Metastatic Sites
Even in the absence of a definitive primary site, it is possible to gain insights into the evolutionary dynamics of tumor growth in distinct anatomic compartments. A case in point is WCM642, a 50-year-old male patient who presented with disseminated disease from a primary tumor of unknown origin (Fig 3) . Prior biopsy demonstrated an epithelioid neoplasm without a definitive diagnosis. At autopsy, tumor was frozen from 15 distinctly annotated anatomic locations including adrenal gland and three distinct lobes of the lungs (Figs 3A and 3B), parietal pleura, omentum, lymphnodes (three distinct sites), small intestine, large intestine, liver (two distinct lobes), gallbladder, and pancreas. Diagnosis of this tumor was only ascertained at autopsy. At autopsy, cells demonstrated both epithelioid and sarcomatoid morphology (Figs 3C and 3D ) and focal positive staining for S100 (not shown), which had been negative in the biopsy. Sequencing revealed mutationsin NRAS and IDH1 ( Fig 3E) and contributed to the final diagnosis of malignant melanoma.
Reconstruction of the clonal architecture of eight metastases from this patient demonstrated several mutations that were shared in all samples (MLLT4, IDH1, AFF3, ARID2, ECT2L, and NRAS), as well as mutations restricted to particular metastatic sites (eg, APC in an LM and SMAD4 in lung; Fig 3F) . Remarkably, the branch points of the phylogenetic tree reflect the anatomic distribution of metastases, with those encompassing the digestive system grouped separately from those to the adrenal gland and lungs. Moreover, metastases to the small and large intestines are more closely related with each other than with those to the liver and pancreas. These findings also correlate with site-specific alterations such as ANKRD52, which was mutated in three of three distinct lung metastases but in zero of five other metastatic sites tested.
In other patients, such as WCM0 (small-cell carcinoma of prostate) and WCM772 (pleomorphic carcinoma of lung), RNA-Seq data were used to further enhance comparisons across metastatic sites. In particular, for both of these patients, genes were identified that showed consistent overexpression across metastatic tumors for each patient at the transcriptional level relative to the expression of these genes over a large set of RNA-Seq samples. The latter analysis derived from diverse tumors over the accrued transcriptome profiling from the precision medicine clinical trial cohort (n =300 samples). In the case of WCM0, CDKN2C was identified as an outlier across multiple sites, and in WCM772, MET was consistently overexpressed (Fig 4A) . For WCM772, these data correlated with evidence of amplification of the MET gene derived from WES, whereas for WCM0, no such correlation was observed (Data Supplement). Additional RNA-Seq analysis of WCM0 samples identified novel gene fusion candidates such as ZNF526-MEGF8 (Figs 4B to 4D ).
In addition, WGS on two LMs from this patient yielded additional candidates, including the discovery of a gene fusion involving STYK1, a putative serine/threonine and tyrosine receptor protein kinase of potential clinical significance in castrate-resistant prostate cancer 32 (Fig 5) .
Tumor Organoid, PDX, and Cell Line Development
PDXs and cell lines are the most frequently used models in cancer research and anticancer drug screening. The tumor organoid model is a major in vitro break through that has the potential to study in vivo biologic processes and may provide a new avenue for personalized cancer care. 33, 34 As demonstrated in patient WCM331, despite a delayed PMI of 6.5 hours as a result of transportation from an outside hospital, tumor organoid development of ovarian serous adenocarcinoma was achieved. Upon opening the peritoneal cavity, disseminated carcinomatosis was readily observed (Fig 6A) , and tumor tissue was immediately placed into culture media. Viable organoids histologically comparable to metastatic autopsy tissue were produced and consistent with ovarian serous adenocarcinoma (Figs 6B to 6D) . WES was performed on a metastatic omental lesion biopsied 2 years before autopsy, on several metastatic lesions obtained at autopsy, and on the tumor organoid material derived from a peritoneal nodule obtained at autopsy. The analysis demonstrates genetic alterations that are shared across these specimens ( Figs 6E and 6F) . Reconstruction of the clonal architecture of metastatic samples and tumor organoid demonstrates that PTPRB mutation is shared across all samples, whereas FOXO1 mutation is present in one metastasis (to small bowel serosa) and the tumor organoid only. At the same time, differences in certain alterations may reflect heterogeneity in disease across time and anatomic location. Alterations restricted to the tumor organoid material only (eg, PRDM16 and KMT2A) may reflect either additional tumor heterogeneity or alterations arising in vitro.
Another example of patient-derived preclinical model development from rapid autopsy tissue is illustrated in a patient with colon adenocarcinoma (WCM715; Fig 6G) for whom both tumor organoid (Figs 6H and 6I) and downstream PDX models (Fig 6J) were established. In addition to successful PDX development using cells directly harvested from rapid autopsy material (eg, prostate cancer in patient WCM677), cell line development was also pursued (eg, diffuse midline glioma in patient WCM627, with viable passages to date; data not shown).
DISCUSSION
Tissue procurement from patients with cancer at autopsy and within the context of a pancancer precision medicine clinical trial captures biologic data at a state in disease progression that is rarely studied. In contrast to previously reported autopsy programs, we have incorporated data analysis and development of preclinical models using multiple platforms, 2 clinical-grade assays, 13 and computational algorithms, 13, 35, 36 leveraging the infrastructure of IPM. Here, we illustrate a proof of principle in developing a powerful model for interrogating a diverse set of primary tumor types and metastatic sites, including newly generated tumor organoids, PDX models, and cell culture. Indeed, with just the first 15 autopsies, we have revealed novel genetic candidates as potential mediators of metastatic spread in both ependymoma and melanoma, as well as provided the foundation for additional work investigating treatment effect in metastatic urothelial carcinoma.
As a testament to our ability to track patients through their disease course, we analyzed primary tumor samples in 77% of patients for whom metastatic disease was procured at autopsy and in 80% of patients overall. Moreover, prior surgically obtained premortem tumor material (either primary or metastatic) was available for study in 87% of patients, enabling in the vast majority of patients the potential to study tumor evolution over time and through diverse therapeutic modalities.
We have demonstrated that analysis of WES data of rapid autopsy material in the context of a precision medicine clinical trial permits the identification of genes that become altered at biologically significant branch points in tumor evolution, including those that may contribute to metastatic potential or treatment resistance. For example, analysis of WCM419 revealed alterations in CUL9 and PIGM that were present in most or all spatiotemporally distinct metastatic sites of ependymoma but absent from multiple resections at the primary site. CUL9, which encodes a putative E3 ubiquitin ligase that binds to p53, has been described as a tumor suppressor, 37 whereas PIGM encodes a mannosyltransferase involved in glycosylphosphatidylinositol-anchor biosynthesis. 38 In addition, we have identified gene candidates for further study that may mediate organotropism of metastases in melanoma; for example, we found that ANKRD52 mutations were restricted to lung metastases in a patient with widely metastatic melanoma. Finally, additional work on two patients from within this cohort (WCM117 and WCM259) has already yielded further insights into chemotherapyresistant urothelial carcinoma, demonstrating enrichment in clonal alterations including targetable mutations (eg, L1CAM and integrin signaling pathways). 21 Comparison of WES between primary tumors, metastatic sites, and preclinical in vitro models of disease also enables an assessment of the extent to which critical molecular features of a tumor are reiterated, for example, in tumor organoids. The latter seem to recapitulate the patient's metastatic disease at the exome level, representing an opportunity to develop coclinical trials and other clinically relevant applications (discussed in additional detail by Pauli et al 39 ). In addition, investigation of WGS and RNA-Seq data including gene expression outlier analysis across our precision medicine cohort has allowed the identification of novel gene fusions and overexpression of certain transcripts across metastatic sites with potential clinical relevance.
We have set the foundation to investigate several critical questions over a diverse set of neoplasms, including the temporal evolution of tumors, the clonal evolution of tumors with respect to widely disseminated metastatic disease sites, and the production and examination of tumor organoid models derived from these specimens. Performing additional drug screening on preclinical platforms developed from autopsy tissue has the potential of benefiting future patients with molecularly similar tumors. Analyses of the data in each one of these extremely valuable patients is ongoing, with the goal of gleaning as much information as possible from every patient.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. (E) Whole-exome sequencing was performed on formalin-fixed paraffin-embedded material derived from an omental metastasis biopsied 2 years before autopsy (sample 1), on frozen material from two metastases obtained at autopsy (samples 2 and 3), and on tumor organoid material derived from a peritoneal nodule obtained at autopsy (sample 4). Both the colorcoded bar on the right and the phylogenetic tree below indicate whether mutations are private to the metastatic sites or are shared in more than one sample or in all samples. Multiple genetic alterations are shared across these specimens ranging from one (eg, FOXO1) to all samples (eg, PTPRB). This molecular evidence supports that the tumor organoid recapitulates the patient's metastatic disease. (F) In the absence of material from the primary tumor, partial reconstruction of the clonal evolution of metastatic samples (including the tumor organoid as surrogate of one of the metastasis at autopsy) demonstrates that PTPRB mutation is shared in all samples and FOXO1 mutation is present in two metastases. Some alterations were seen in the tumor organoidonly (eg, PRDM16 and KMT2A).(G)Incase WCM715, an HE-stained section of a liver metastasis obtained at autopsy showed metastatic mucinous adenocarcinoma of the colon (×200 original magnification). (H) Smear preparation of tumor organoid culture (Diff-Quik stain) to confirm tumor growth (×400 original magnification). (I) HE-stained section of formalinfixed paraffin-embedded organoid (×200 original magnification). (J) HE-stained section of patient-derived xenograft derived from organoid implantation in mouse demonstrates
